Understanding how to disable c-Myc could revolutionize cancer treatment, given this oncoprotein drives tumor growth in roughly seven out of ten cancers. The challenge has been that c-Myc was long considered "undruggable" due to its central role in normal cell function and lack of accessible binding sites for therapeutic molecules. This new research reveals that crotonylation, a specific chemical modification involving the attachment of crotonyl groups to the c-Myc protein, significantly impairs its cancer-promoting capabilities. The modification appears to interfere with c-Myc's ability to bind DNA and activate the gene programs that fuel uncontrolled cell division and tumor progression. Laboratory experiments demonstrated that when crotonylation levels increase, c-Myc's oncogenic activity decreases proportionally, suggesting a natural regulatory mechanism that cancer cells may have disrupted. The crotonyl modification occurs through enzymatic processes that cells can potentially control, unlike permanent genetic mutations. This finding opens entirely new therapeutic avenues beyond traditional approaches that attempt to block c-Myc directly. Rather than targeting the protein itself, treatments could focus on enhancing crotonylation pathways to naturally suppress c-Myc function. The approach represents a paradigm shift from inhibition to modification-based cancer control. However, significant limitations remain before clinical application. The research utilized cell culture models, and the complexity of crotonylation regulation in human tumors requires extensive investigation. Questions persist about whether enhancing crotonylation might interfere with normal c-Myc functions essential for healthy cell renewal. Additionally, cancer cells' notorious ability to develop resistance mechanisms could potentially circumvent crotonylation-based therapies. Despite these challenges, the discovery provides the first clear evidence that c-Myc's oncogenic power can be chemically regulated through natural cellular processes.